BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guenova E, Teske A, Fehrenbacher B, Hoerber S, Adamczyk A, Schaller M, Hoetzenecker W, Biedermann T. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol. 2011;147:1203-1205. [PMID: 21680759 DOI: 10.1001/archdermatol.2011.168] [Cited by in Crossref: 100] [Cited by in F6Publishing: 74] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Barbosa NS, Tolkachjov SN, el-Azhary RA, Davis MD, Camilleri MJ, Mcevoy MT, Bridges AG, Wetter DA. Clinical features, causes, treatments, and outcomes of peristomal pyoderma gangrenosum (PPG) in 44 patients: The Mayo Clinic experience, 1996 through 2013. Journal of the American Academy of Dermatology 2016;75:931-9. [DOI: 10.1016/j.jaad.2016.05.044] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 5.4] [Reference Citation Analysis]
2 Wu BC, Patel ED, Ortega-Loayza AG. Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. Br J Dermatol 2017;177:72-83. [PMID: 27864925 DOI: 10.1111/bjd.15193] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
3 Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol. 2015;73:691-698. [PMID: 26253362 DOI: 10.1016/j.jaad.2015.06.021] [Cited by in Crossref: 116] [Cited by in F6Publishing: 59] [Article Influence: 19.3] [Reference Citation Analysis]
4 Monari P, Moro R, Motolese A, Misciali C, Baraldi C, Fanti PA, Caccavale S, Puviani M, Olezzi D, Zampieri P, Trevisan G, Nan K, Fiorentini C, Pellacani G, Gualdi G. Epidemiology of pyoderma gangrenosum: Results from an Italian prospective multicentre study. Int Wound J 2018;15:875-9. [PMID: 29877043 DOI: 10.1111/iwj.12939] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
5 Vallini V, Andreini R, Bonadio A. Pyoderma Gangrenosum: A Current Problem as Much as an Unknown One. The International Journal of Lower Extremity Wounds 2017;16:191-201. [DOI: 10.1177/1534734617710980] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Choe H, Sakano H, Takigami H, Inaba Y, Matsuo K, Saito T. Pyoderma Gangrenosum With Wrist Joint Destruction: Case Report. The Journal of Hand Surgery 2013;38:357-61. [DOI: 10.1016/j.jhsa.2012.10.049] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
7 Ohtsuka M, Yamamoto T. Rare association of pyoderma gangrenosum and palmoplantar pustulosis: a case report and review of the previous works. J Dermatol. 2014;41:732-735. [PMID: 24986043 DOI: 10.1111/1346-8138.12543] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
8 Phillips FM, Verstockt B, Sebastian S, Ribaldone D, Vavricka S, Katsanos K, Slattery E, de Suray N, Flores C, Fries W, Vincenzi F, Capoferro E, Bachmann O, Kopylov U. Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series. J Crohns Colitis 2020;14:1488-93. [PMID: 32318735 DOI: 10.1093/ecco-jcc/jjaa078] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
9 Chandler D, Bewley A. Biologics in dermatology. Pharmaceuticals (Basel) 2013;6:557-78. [PMID: 24276125 DOI: 10.3390/ph6040557] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
10 Romano C, Esposito S, Ferrara R, Cuomo G. Choosing the most appropriate biologic therapy for Crohn’s disease according to concomitant extra-intestinal manifestations, comorbidities, or physiologic conditions. Expert Opinion on Biological Therapy 2020;20:49-62. [DOI: 10.1080/14712598.2020.1689953] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Selva-nayagam P, Fischer G, Hamann I, Sobel J, James C. Rituximab Causing Deep Ulcerative Suppurative Vaginitis/Pyoderma Gangrenosum. Curr Infect Dis Rep 2015;17. [DOI: 10.1007/s11908-015-0478-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
12 Jauregui-Amezaga A, Somers M, De Schepper H, Macken E. Next generation of biologics for the treatment of Crohn's disease: an evidence-based review on ustekinumab. Clin Exp Gastroenterol. 2017;10:293-301. [PMID: 29180886 DOI: 10.2147/ceg.s110546] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
13 Al Ghazal P, Dissemond J. Therapy of pyoderma gangrenosum in Germany: results of a survey among wound experts. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2015;13:317-24. [DOI: 10.1111/ddg.12585] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
14 Cugno M, Borghi A, Marzano AV. PAPA, PASH and PAPASH Syndromes: Pathophysiology, Presentation and Treatment. Am J Clin Dermatol 2017;18:555-62. [DOI: 10.1007/s40257-017-0265-1] [Cited by in Crossref: 61] [Cited by in F6Publishing: 35] [Article Influence: 15.3] [Reference Citation Analysis]
15 Savage LJ, Wittmann M, McGonagle D, Helliwell PS. Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis. Rheumatol Ther. 2015;2:1-16. [PMID: 27747495 DOI: 10.1007/s40744-015-0010-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
16 Piqueras-garcía J, Sahuquillo-torralba A, Torres-navarro I, Botella-estrada R. Pioderma gangrenoso asociado a colitis ulcerosa con buena respuesta a ustekinumab. Actas Dermo-Sifiliográficas 2019;110:776-8. [DOI: 10.1016/j.ad.2018.03.034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
17 Quaglino P, Fava P, Caproni M, Antiga E, De Simone C, Papini M, Parodi A, Novelli M, Osella-abate S, Ribero S, Sanlorenzo M, Ponti R, Fierro M, Marzano A, Savoia P. Phenotypical characterization of circulating cell subsets in pyoderma gangrenosum patients: the experience of the Italian immuno-pathology group. J Eur Acad Dermatol Venereol 2016;30:655-8. [DOI: 10.1111/jdv.13100] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
18 Schadt CR, Callen JP. Management of neutrophilic dermatoses. Dermatol Ther 2012;25:158-72. [PMID: 22741935 DOI: 10.1111/j.1529-8019.2012.01488.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
19 Plumptre I, Knabel D, Tomecki K. Pyoderma Gangrenosum: A Review for the Gastroenterologist. Inflamm Bowel Dis 2018;24:2510-7. [PMID: 29788368 DOI: 10.1093/ibd/izy174] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
20 Butler D, Shinkai K. What Do Autoinflammatory Syndromes Teach About Common Cutaneous Diseases Such as Pyoderma Gangrenosum? A Commentary. Dermatologic Clinics 2013;31:427-35. [DOI: 10.1016/j.det.2013.04.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
21 Petty AJ, Whitley MJ, Balaban A, Ellington K, Marano AL. Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab. JAAD Case Rep 2020;6:731-3. [PMID: 32715064 DOI: 10.1016/j.jdcr.2020.06.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment. Expert Rev Clin Immunol 2018;14:225-33. [PMID: 29406827 DOI: 10.1080/1744666X.2018.1438269] [Cited by in Crossref: 41] [Cited by in F6Publishing: 8] [Article Influence: 13.7] [Reference Citation Analysis]
23 McKenzie F, Cash D, Gupta A, Cummings LW, Ortega-Loayza AG. Biologic and small-molecule medications in the management of pyoderma gangrenosum. J Dermatolog Treat 2019;30:264-76. [PMID: 30051737 DOI: 10.1080/09546634.2018.1506083] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
24 Benzaquen M, Monnier J, Beaussault Y, Rouby F, Berbis P. Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: Effectiveness of ustekinumab. Australas J Dermatol 2017;58:e270-1. [PMID: 28660635 DOI: 10.1111/ajd.12545] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
25 Maalouf D, Battistella M, Bouaziz J. Neutrophilic dermatosis: disease mechanism and treatment. Current Opinion in Hematology 2015;22:23-9. [DOI: 10.1097/moh.0000000000000100] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 5.2] [Reference Citation Analysis]
26 Westerdahl JS, Nusbaum KB, Chung CG, Kaffenberger BH, Ortega-Loayza AG. Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes. J Dermatolog Treat 2021;:1-5. [PMID: 34057010 DOI: 10.1080/09546634.2021.1937475] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Caproni M, Antiga E, Volpi W, Verdelli A, Venegoni L, Quaglino P, Fabbri P, Marzano A. The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum. Br J Dermatol 2015;173:275-8. [DOI: 10.1111/bjd.13670] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
28 Marzano AV, Fanoni D, Antiga E, Quaglino P, Caproni M, Crosti C, Meroni PL, Cugno M. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome. Clin Exp Immunol 2014;178:48-56. [PMID: 24903614 DOI: 10.1111/cei.12394] [Cited by in Crossref: 141] [Cited by in F6Publishing: 95] [Article Influence: 20.1] [Reference Citation Analysis]
29 Kolios AGA, Hafner J, Luder C, Guenova E, Kerl K, Kempf W, Nilsson J, French LE, Cozzio A. Comparison of pyoderma gangrenosum and Martorell hypertensive ischaemic leg ulcer in a Swiss cohort. Br J Dermatol 2018;178:e125-6. [PMID: 28832960 DOI: 10.1111/bjd.15901] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
30 Agollah GD, Wu G, Peng HL, Kwon S. Dextran sulfate sodium-induced acute colitis impairs dermal lymphatic function in mice. World J Gastroenterol. 2015;21:12767-12777. [PMID: 26668501 DOI: 10.3748/wjg.v21.i45.12767] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
31 Low ZM, Mar A. Treatment of severe recalcitrant pyoderma gangrenosum with ustekinumab. Australas J Dermatol 2018;59:131-4. [PMID: 29205260 DOI: 10.1111/ajd.12744] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
32 Marzano AV, Ortega-Loayza AG, Heath M, Morse D, Genovese G, Cugno M. Mechanisms of Inflammation in Neutrophil-Mediated Skin Diseases. Front Immunol 2019;10:1059. [PMID: 31139187 DOI: 10.3389/fimmu.2019.01059] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 15.0] [Reference Citation Analysis]
33 Shanmugam VK, Angra D, Rahimi H, McNish S. Vasculitic and autoimmune wounds. J Vasc Surg Venous Lymphat Disord 2017;5:280-92. [PMID: 28214498 DOI: 10.1016/j.jvsv.2016.09.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 6.6] [Reference Citation Analysis]
34 Marzano AV, Ishak RS, Saibeni S, Crosti C, Meroni PL, Cugno M. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol. 2013;45:202-210. [PMID: 23334898 DOI: 10.1007/s12016-012-8351-x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 59] [Article Influence: 13.7] [Reference Citation Analysis]
35 Teagle A, Hargest R. Management of pyoderma gangrenosum. J R Soc Med 2014;107:228-36. [PMID: 24912791 DOI: 10.1177/0141076814534407] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
36 Tolkachjov SN, Fahy AS, Wetter DA, Brough KR, Bridges AG, Davis MD, el-Azhary RA, Mcevoy MT, Camilleri MJ. Postoperative pyoderma gangrenosum (PG): The Mayo Clinic experience of 20 years from 1994 through 2014. Journal of the American Academy of Dermatology 2015;73:615-22. [DOI: 10.1016/j.jaad.2015.06.054] [Cited by in Crossref: 56] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
37 Maverakis E, Marzano AV, Le ST, Callen JP, Brüggen M, Guenova E, Dissemond J, Shinkai K, Langan SM. Pyoderma gangrenosum. Nat Rev Dis Primers 2020;6. [DOI: 10.1038/s41572-020-0213-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
38 Pukar C, Sudha A, Punam P. Simultaneous occurrence of Pyoderma Gangrenosum and Palmoplantar Pustular Psoriasis: Is it an association or coincidental findings? Clin Case Rep 2021;9:410-5. [PMID: 33489191 DOI: 10.1002/ccr3.3544] [Reference Citation Analysis]
39 Speeckaert R, Lambert J, Grine L, Van Gele M, De Schepper S, van Geel N. The many faces of interleukin-17 in inflammatory skin diseases. Br J Dermatol 2016;175:892-901. [PMID: 27117954 DOI: 10.1111/bjd.14703] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
40 Prat L, Bouaziz JD, Wallach D, Vignon-Pennamen MD, Bagot M. Neutrophilic dermatoses as systemic diseases. Clin Dermatol 2014;32:376-88. [PMID: 24767185 DOI: 10.1016/j.clindermatol.2013.11.004] [Cited by in Crossref: 71] [Cited by in F6Publishing: 39] [Article Influence: 8.9] [Reference Citation Analysis]
41 Khan F, Radovanovic A, Gojobori T, Kaur M. IBDDB: a manually curated and text-mining-enhanced database of genes involved in inflammatory bowel disease. Database (Oxford) 2021;2021:baab022. [PMID: 33929018 DOI: 10.1093/database/baab022] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Guillo L, D’amico F, Danese S, Peyrin-biroulet L. Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review. Journal of Crohn's and Colitis 2021;15:1236-43. [DOI: 10.1093/ecco-jcc/jjaa260] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
43 Hadian Y, Bagood MD, Dahle SE, Sood A, Isseroff RR. Interleukin-17: Potential Target for Chronic Wounds. Mediators Inflamm 2019;2019:1297675. [PMID: 31827374 DOI: 10.1155/2019/1297675] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
44 López González J, Lázaro Sáez M, Moreno Moraleda I, Hernández Martínez Á. Pyoderma gangrenosum solved by ustekinumab therapy. Gastroenterol Hepatol 2021;44:299-300. [PMID: 33069432 DOI: 10.1016/j.gastrohep.2020.06.027] [Reference Citation Analysis]
45 Khanna R, Feagan BG. Ustekinumab for the treatment of Crohn’s disease. Immunotherapy. 2013;5:803-815. [PMID: 23902548 DOI: 10.2217/imt.13.81] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
46 Deepak P, Loftus EV Jr. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy. Drug Des Devel Ther 2016;10:3685-98. [PMID: 27956825 DOI: 10.2147/DDDT.S102141] [Cited by in Crossref: 29] [Cited by in F6Publishing: 7] [Article Influence: 5.8] [Reference Citation Analysis]
47 Hobbs MM, Ortega-Loayza AG. Pyoderma gangrenosum: From historical perspectives to emerging investigations. Int Wound J 2020;17:1255-65. [PMID: 32378319 DOI: 10.1111/iwj.13389] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
48 Szalat R, Monsel G, Le Goff W, Battistella M, Bengouffa D, Schlageter M, Bouaziz J, Arnulf B, Vignon M, Lesnik P, Saussine A, Malphettes M, Lazareth A, Vignon-pennamen M, Bagot M, Brouet J, Fermand J, Rybojad M, Asli B. The spectrum of neutrophilic dermatoses associated with monoclonal gammopathy: Association with IgA isotype and inflammatory profile. Journal of the American Academy of Dermatology 2015;73:809-20. [DOI: 10.1016/j.jaad.2015.07.031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
49 Fallen RS, Terpstra CR, Lima HC. Immunotherapies in Dermatologic Disorders. Medical Clinics of North America 2012;96:565-82. [DOI: 10.1016/j.mcna.2012.04.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
50 Ohashi T, Miura T, Yamamoto T. Auricular pyoderma gangrenosum with penetration in a patient with rheumatoid arthritis. Int J Rheum Dis. 2014;Jun 10; Epub ahead of print. [PMID: 24916772 DOI: 10.1111/1756-185x.12411] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
51 Greb JE, Gottlieb AB, Goldminz AM. High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum. Dermatol Ther 2016;29:482-3. [PMID: 27502191 DOI: 10.1111/dth.12387] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
52 Alavi A, French LE, Davis MD, Brassard A, Kirsner RS. Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment. Am J Clin Dermatol. 2017;18:355-372. [PMID: 28224502 DOI: 10.1007/s40257-017-0251-7] [Cited by in Crossref: 98] [Cited by in F6Publishing: 52] [Article Influence: 32.7] [Reference Citation Analysis]
53 Wu XR, Shen B. Diagnosis and management of parastomal pyoderma gangrenosum. Gastroenterol Rep (Oxf) 2013;1:1-8. [PMID: 24759661 DOI: 10.1093/gastro/got013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
54 Deepak P, Sandborn WJ. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease. Gastroenterol Clin North Am 2017;46:603-26. [PMID: 28838418 DOI: 10.1016/j.gtc.2017.05.013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
55 Goldminz AM, Botto NC, Gottlieb AB. Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab. Journal of the American Academy of Dermatology 2012;67:e237-8. [DOI: 10.1016/j.jaad.2012.04.045] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
56 Quist SR, Kraas L. Treatment options for pyoderma gangrenosum. J Dtsch Dermatol Ges 2017;15:34-40. [PMID: 28140549 DOI: 10.1111/ddg.13173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
57 Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol. 2012;13:191-211. [PMID: 22356259 DOI: 10.2165/11595240-000000000-00000] [Cited by in Crossref: 209] [Cited by in F6Publishing: 115] [Article Influence: 23.2] [Reference Citation Analysis]
58 Marzano AV, Ceccherini I, Gattorno M, Fanoni D, Caroli F, Rusmini M, Grossi A, De Simone C, Borghi OM, Meroni PL, Crosti C, Cugno M. Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. Medicine (Baltimore) 2014;93:e187. [PMID: 25501066 DOI: 10.1097/MD.0000000000000187] [Cited by in Crossref: 75] [Cited by in F6Publishing: 19] [Article Influence: 12.5] [Reference Citation Analysis]
59 Cosgarea I, Lovric Z, Körber A, Dissemond J. Successful treatment of refractory pyoderma gangrenosum with ustekinumab only after excision of renal cell carcinoma. Int Wound J 2016;13:1041-2. [PMID: 25294697 DOI: 10.1111/iwj.12377] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
60 Deregnaucourt D, Buche S, Coopman S, Basraoui D, Turck D, Delaporte E. Pyoderma gangrenosum avec localisations pulmonaires traité par infliximab. Annales de Dermatologie et de Vénéréologie 2013;140:363-6. [DOI: 10.1016/j.annder.2013.01.428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
61 de Risi-pugliese T, Seksik P, Bouaziz J, Chasset F, Moguelet P, Gornet J, Bourrier A, Amiot A, Beaugerie L, Francès C, Guégan S, Coffin B, Pariente B, Abitbol V, Simon M, Chantelou E. Ustekinumab treatment for neutrophilic dermatoses associated with Crohn's disease: A multicenter retrospective study. Journal of the American Academy of Dermatology 2019;80:781-4. [DOI: 10.1016/j.jaad.2018.06.065] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
62 Yamamoto T. Pyoderma gangrenosum: An important dermatologic condition occasionally associated with rheumatic diseases. WJR 2015;5:101. [DOI: 10.5499/wjr.v5.i2.101] [Cited by in CrossRef: 3] [Article Influence: 0.5] [Reference Citation Analysis]
63 Antiga E, Maglie R, Volpi W, Bianchi B, Berti E, Marzano AV, Caproni M. T helper type 1-related molecules as well as interleukin-15 are hyperexpressed in the skin lesions of patients with pyoderma gangrenosum. Clin Exp Immunol 2017;189:383-91. [PMID: 28518224 DOI: 10.1111/cei.12989] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
64 Mckenzie F, Arthur M, Ortega-loayza AG. Pyoderma Gangrenosum: What Do We Know Now? Curr Derm Rep 2018;7:147-57. [DOI: 10.1007/s13671-018-0224-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
65 Fahmy M, Ramamoorthy S, Hata T, Sandborn WJ. Ustekinumab for Peristomal Pyoderma Gangrenosum. American Journal of Gastroenterology 2012;107:794-5. [DOI: 10.1038/ajg.2012.42] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
66 Kelly G, Sweeney CM, Tobin AM, Kirby B. Hidradenitis suppurativa: the role of immune dysregulation. Int J Dermatol. 2014;53:1186-1196. [PMID: 24961484 DOI: 10.1111/ijd.12550] [Cited by in Crossref: 63] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
67 Eisendle K, Thuile T, Deluca J, Pichler M. Surgical Treatment of Pyoderma Gangrenosum with Negative Pressure Wound Therapy and Skin Grafting, Including Xenografts: Personal Experience and Comprehensive Review on 161 Cases. Adv Wound Care (New Rochelle) 2020;9:405-25. [PMID: 32320362 DOI: 10.1089/wound.2020.1160] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
68 Schlapbach C, Navarini AA. The continuing evolution of targeted therapy for inflammatory skin disease. Semin Immunopathol 2016;38:123-33. [DOI: 10.1007/s00281-015-0524-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
69 Gameiro A, Pereira N, Cardoso JC, Gonçalo M. Pyoderma gangrenosum: challenges and solutions. Clin Cosmet Investig Dermatol 2015;8:285-93. [PMID: 26060412 DOI: 10.2147/CCID.S61202] [Cited by in Crossref: 49] [Cited by in F6Publishing: 8] [Article Influence: 8.2] [Reference Citation Analysis]
70 Nieto D, Sendagorta E, Rueda JM, Herranz P. Successful treatment with ustekinumab and vacuum-assisted closure therapy in recalcitrant myelodysplastic syndrome-associated pyoderma gangrenosum: case report and literature review. Clin Exp Dermatol 2019;44:116-9. [DOI: 10.1111/ced.13679] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
71 García Cámara P, Zubiri Ara ML, García López S. Ustekinumab en un paciente con pioderma gangrenoso y enfermedad de Crohn refractaria. Medicina Clínica 2019;153:e35-6. [DOI: 10.1016/j.medcli.2018.12.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
72 Huang BL, Chandra S, Shih DQ. Skin manifestations of inflammatory bowel disease. Front Physiol. 2012;3:13. [PMID: 22347192 DOI: 10.3389/fphys.2012.00013] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 7.9] [Reference Citation Analysis]
73 Havnaer A, Han G. Autoinflammatory Disorders: A Review and Update on Pathogenesis and Treatment. Am J Clin Dermatol 2019;20:539-64. [DOI: 10.1007/s40257-019-00440-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
74 Almutairi D, Leblanc K, Alavi A. Peristomal skin complications: what dermatologists need to know. Int J Dermatol 2018;57:257-64. [DOI: 10.1111/ijd.13710] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]